Progression-free survival according to randomization. Seventy (80%) of the patients in the fludarabine arm progressed as did 74 (77%) in the chlorambucil arm. Median progression-free survival was 18 months in the chlorambucil arm versus 19 months in the fludarabine arm (P = .7).